Competing interests: MJK has received research support from Kite/Gilead; honoraria for advisory boards and/or presentations from Beigene, Kite/Gilead, Miltenyi Biotec, Novartis, Adicet Bio, Mustang Bio, Roche, and BMS (all to institution); and travel support for conferences from Beigene, Roche, and BMS. SO has acted as a consultant/advisor for AbbVie, AstraZeneca, BeiGene, Janssen, Gilead, Merck and Bristol Myers Squibb; his institution has received research funding from AbbVie, BeiGene, Janssen, Gilead, Pharmacyclics, Roche, and Ipsen; and has received honoraria from AbbVie, AstraZeneca, BeiGene, Janssen, Gilead, Merck and Bristol Myers Squibb. RTS received honoraria from Janssen, AbbVie, Roche, AstraZeneca, BeiGene. SKT has received research support from Sanofi, Bristol Myers Squibb, Cellectar Biosciences, and Abbvie, and has served on the advisory board of Cellectar Biosciences and Mustang Bio. SD’S has received speaker fees, honoraria, congress support, research support and is on the advisory board for Beigene; advisory board for Sanofi, and Cellectar. MCM received research funding from Beigene, Speakers fee from Janssen Cilag, Siemens, and Springer Healthcare, and Consultancy fee from Janssen Cilag, Pfizer, BMS, GSK, and Hospitality Janssen Cilag. JMIV has received the following as institutional honoraria: research support from Beigene and AbbVie/Genmab; advisory board/consultancy fees from Sanofi and Janssen; and speaker fees from BMS, Sanofi, Beigene, Novartis, and Amgen. ALB, JPMvdM, OT, TWHF, NJ, JK, SK, HL, SM, SS, and AFJEV declare no potential competing interests.